- Home
- LYFT vs GH Comparison
LYFT vs GH Comparison
Compare LYFT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYFT | GH |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | 3913 | N/A |
| Industry | Business Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 22.9B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LYFT | GH |
|---|---|---|
| Price | $14.90 | $177.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 29 | 19 |
| Target Price | $20.07 | ★ $119.79 |
| AVG Volume (30 Days) | ★ 9.0M | 1.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11250.00 | 6.74 |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $6,316,261,000.00 | $982,021,000.00 |
| Revenue This Year | $17.33 | $33.30 |
| Revenue Next Year | $12.29 | $28.27 |
| P/E Ratio | $92.19 | ★ N/A |
| Revenue Growth | 9.16 | ★ 32.88 |
| 52 Week Low | $12.46 | $59.63 |
| 52 Week High | $25.54 | $183.51 |
Technical Indicators
Market Signals| Indicator | LYFT | GH |
|---|---|---|
| Relative Strength Index (RSI) | 38.46 | 58.86 |
| Support Level | $12.85 | $153.88 |
| Resistance Level | $15.15 | $183.51 |
| Average True Range (ATR) | 0.52 | 7.86 |
| MACD | -0.12 | 0.63 |
| Stochastic Oscillator | 21.10 | 76.19 |
Price Performance
Historical ComparisonAbout LYFT Lyft Inc.
Lyft is the second-largest ride-sharing service provider in North America, connecting riders and drivers over the Lyft app. Incorporated in 2013 and public since 2019, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury rides. Beyond ride-hailing, Lyft has entered the bike- and scooter-share market to offer multimodal transportation options.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.